Table 3.
Multivariate Cox regression analysis of disease-free survival in esophageal squamous cell carcinoma.
| Variable | Categories | 7th-edition staging, SUVmax (median cutoff) | 7th-edition staging, SUVmax (best cutoff) | 8th-edition staging, SUVmax (median cutoff) | 8th-edition staging, SUVmax (best cutoff) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hazard ratio | 95% confidence interval | p | Hazard ratio | 95% confidence interval | p | Hazard ratio | 95% confidence interval | p | Hazard ratio | 95% confidence interval | p | ||
| Sex | Female vs. Male | 1.989 | 0.970–4.082 | 0.061 | 2.043 | 0.995–4.194 | 0.052 | 2.110 | 1.030–4.322 | 0.041 | 2.153 | 1.050–4.412 | 0.036 |
| Clinical N stage |
N0 | ||||||||||||
| N1 | 1.491 | 1.063–2.091 | 0.021 | 1.456 | 1.040–2.037 | 0.029 | 1.507 | 1.074–2.116 | 0.018 | 1.473 | 1.052–2.062 | 0.024 | |
| N2 | 1.101 | 0.657–1.844 | 0.716 | 1.107 | 0.664–1.845 | 0.697 | 1.291 | 0.771–2.159 | 0.331 | 1.308 | 0.785–2.178 | 0.303 | |
| N3 | 2.222 | 0.641–7.709 | 0.208 | 2.772 | 0.796–9.652 | 0.109 | 2.821 | 0.829–9.600 | 0.097 | 3.410 | 0.996–11.673 | 0.051 | |
| Adjuvant therapy | No | ||||||||||||
| CCRT | 0.526 | 0.159–1.736 | 0.292 | 0.563 | 0.171–1.853 | 0.344 | 0.639 | 0.193–2.119 | 0.464 | 0.681 | 0.206–2.252 | 0.529 | |
| RT | 2.173 | 0.874–5.403 | 0.095 | 2.385 | 0.959–5.933 | 0.062 | 2.348 | 0.933–5.912 | 0.070 | 2.478 | 0.986–6.228 | 0.054 | |
| CT | 0.742 | 0.540–1.075 | 0.121 | 0.796 | 0.565–1.122 | 0.193 | 0.805 | 0.569–1.138 | 0.220 | 0.842 | 0.586–1.189 | 0.328 | |
| Histological grade | 1 | ||||||||||||
| 2 | 0.775 | 0.488–1.231 | 0.280 | 0.748 | 0.471–1.187 | 0.217 | 0.737 | 0.475–1.142 | 0.172 | 0.719 | 0.464–1.113 | 0.139 | |
| 3 | 0.951 | 0.553–1.635 | 0.857 | 0.971 | 0.564–1.672 | 0.916 | 0.874 | 0.520–1.469 | 0.611 | 0.896 | 0.533–1.507 | 0.679 | |
| 7th pathological stage | IA | ||||||||||||
| IB | 1.332 | 0.376–4.720 | 0.657 | 1.232 | 0.347–4.377 | 0.747 | |||||||
| IIA | 1.131 | 0.213–5.996 | 0.885 | 1.008 | 0.193–5.272 | 0.993 | |||||||
| IIB | 1.648 | 0.452–6.013 | 0.449 | 1.387 | 0.381–5.054 | 0.620 | |||||||
| IIIA | 4.648 | 1.278–16.899 | 0.020 | 4.101 | 1.137–14.791 | 0.031 | |||||||
| IIIB | 9.063 | 2.472–33.230 | <0.001 | 8.113 | 2.241–29.368 | 0.001 | |||||||
| IIIC | 11.541 | 3.098–42.984 | <0.001 | 9.376 | 2.539–34.623 | <0.001 | |||||||
| 8th pathological stage | IA | ||||||||||||
| IB | 2.730 | 0.363–20.511 | 0.329 | 2.147 | 0.283–16.272 | 0.460 | |||||||
| IIA | 3.226 | 0.382–27.272 | 0.282 | 2.374 | 0.279–20.202 | 0.429 | |||||||
| IIB | 3.763 | 0.486–29.133 | 0.204 | 2.688 | 0.343–21.085 | 0.347 | |||||||
| IIIA | 5.602 | 0.692–45.356 | 0.106 | 3.972 | 0.487–32.422 | 0.198 | |||||||
| IIIB | 12.610 | 1.632–97.411 | 0.015 | 9.526 | 1.231–73.718 | 0.031 | |||||||
| IVA | 22.485 | 2.844–177.804 | 0.003 | 15.420 | 1.936–122.832 | 0.010 | |||||||
| SUVmax (median cutoff) | <4.7 | ||||||||||||
| ≥4.7 | 2.196 | 1.426–3.381 | <0.001 | 1.999 | 1.286–3.106 | 0.002 | |||||||
| SUVmax (best cutoff) |
<3.4 | ||||||||||||
| ≥3.4 | 3.258 | 1.886–5.687 | <0.001 | 2.982 | 1.703–5.219 | <0.001 | |||||||